CD79B.md
... ...
@@ -20,7 +20,7 @@ This and other common mutations primarily occur in the immunoreceptor tyrosine-b
20 20
21 21
|Entity|Tier|Description |
22 22
|:------:|:----:|--------------------------------------|
23
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene with functional evidence[@davisChronicActiveBcellreceptor2010] [@morinFrequentMutationHistonemodifying2011]|
23
+|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene with functional evidence[@davisChronicActiveBcellreceptor2010;@morinFrequentMutationHistonemodifying2011]|
24 24
|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
25 25
|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
26 26
... ...
@@ -35,7 +35,7 @@ This and other common mutations primarily occur in the immunoreceptor tyrosine-b
35 35
36 36
## CD79B Hotspots
37 37
38
-Mutations at Y196 enhance B-cell receptor (BCR) signaling by preventing the negative regulatory feedback provided by Lyn kinase, a feedback inhibitor of BCR signaling. This results in continuous activation of the NF-κB pathway, promoting tumor cell survival and proliferation.<sup>4</sup>
38
+Mutations at Y196 enhance B-cell receptor (BCR) signaling by preventing the negative regulatory feedback provided by Lyn kinase, a feedback inhibitor of BCR signaling. This results in continuous activation of the NF-κB pathway, promoting tumor cell survival and proliferation.<sup>[@kimCD79BMYD88Mutations2014]</sup>
39 39
40 40
| Chromosome |Coordinate (hg19) | ref>alt | HGVSp |
41 41
| :---:| :---: | :--: | :---: |